Poor
Not Aligned
Patient Risk:
Low
Summary
Only the abuse/misuse safety theme is partially supported by the provided label excerpts. The approval-year and approval-indications claims are not supported by the supplied FDA-approved prescribing information excerpts, and the prompt-provided snippets do not contain evidence for those regulatory historical/indication statements.
Category Scores
Accurate Statements
Unsupported Statements
Vyvanse (lisdexamfetamine) received FDA approval in 2007.
The provided FDA label excerpts do not include FDA approval/approval date information.
Vyvanse was approved by the U.S. Food and Drug Administration for treatment of ADHD in children and adults.
The provided FDA label excerpts do not include the approved indications or indication language.
Vyvanse was approved by the U.S. Food and Drug Administration for binge eating disorder in adults.
The provided FDA label excerpts do not include the approved indications or indication language.
After FDA approval in 2007, Vyvanse began appearing in clinical use and prescriptions soon thereafter in that same year.
The provided FDA label excerpts do not contain any post-approval prescribing/clinical use timeline statements.
Contradictions
Important Omissions
FDA-approved indication/indication section content (e.g., Indications and Usage) needed to verify the ADHD (children/adults) and binge eating disorder (adults) approval claims.
Importance:
Moderate
Label text supporting the FDA approval year and any timeline for clinical use/prescriptions.
Importance:
Moderate
Boxed warning language itself (if the intent is to evaluate boxed warning content), beyond the provided excerpts centered on abuse/misuse; the prompt does not include a labeled boxed warning section.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated are primarily about approval history and indications. No dosing, contraindications, warnings, or safety instructions from the label were incorrectly applied. The provided label excerpts about abuse/misuse are not directly claimed in the user response.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Approval year, approved indications, and post-approval prescribing timeline are not supported by the provided FDA label excerpts.
Suggested Improvement
To align with FDA label, cite or quote the label’s Indications and Usage section (for ADHD and binge eating disorder) and only include approval dates/timelines if present in the provided label excerpts. For safety/boxed-warning claims, directly map each statement to the provided label text (e.g., Warnings and Precautions 5.1, Drug Abuse and Dependence 9.2).